Latest news with #XenonPharmaceuticalsInc
Yahoo
03-06-2025
- Business
- Yahoo
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025. Fireside Chat Presentation Details: Date: Tuesday, June 10, 2025 Time: 3:20-3:55 PM Eastern Time Webcast: Register here Presenter: Ian Mortimer, President and Chief Executive Officer A live audio webcast of the company presentation will be available on the 'Investors' section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit 'Xenon' and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors:Chad FugereVice President, Investor Relations(857) 675-7275investors@ For Media:Colleen AlabisoSenior Vice President, Corporate Affairs(617) 671-9238media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
14-05-2025
- Business
- Hamilton Spectator
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025. Fireside Chat Presentation Details: Date: Wednesday, May 21, 2025 Time: 10:30-10:55 AM Eastern Time Webcast: Register here Presenter: Ian Mortimer, President and Chief Executive Officer A live audio webcast of the company presentation will be available on the ' Investors ' section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit . 'Xenon' and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors: Chad Fugere Vice President, Investor Relations (857) 675-7275 investors@ For Media: Colleen Alabiso Senior Vice President, Corporate Affairs (617) 671-9238 media@
Yahoo
14-05-2025
- Business
- Yahoo
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday
We recently published an article titled . In this article, we are going to take a look at where Xenon Pharmaceuticals Inc. (NASDAQ:XENE) stands against the other stocks. Wall Street's main indices finished mixed on Tuesday, as investors digested the country's latest inflation figures, which came out lower than expected. On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, bringing the annual inflation rate to 2.3 percent, versus the 2.4 percent in March. It was the lowest annual rate since February 2021. Only the S&P 500 and the tech-heavy Nasdaq registered gains among all major indices, up by 0.72 percent and 1.61 percent, respectively. The Dow Jones, on the other hand, was down by 0.64 percent. Beyond the main indices, 10 firms lagged in performance amid negative news, sparking sell-offs. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A team of scientists in lab coats studying a biopharmaceutical molecule in a lab. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) decreased by 17.43 percent on Tuesday to finish at $29.60 apiece following the delayed results of its Phase 3 epilepsy study and a dismal earnings performance in the first quarter of the year. In a statement, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) said that the results of the study are now expected to be released in early 2026. 'While this timing represents a modest shift from our prior guidance, we are encouraged that we are nearing the end of this important study, which represents a significant milestone for Xenon, getting us one step closer to a potential first commercial product launch,' said President and CEO Ian Mortimer. In the first three months of the year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) said net loss widened by 35.7 percent to $65 million from $47.9 million in the same period last year, despite incurring $7.5 million in revenues during the period. Research and development expenses grew by 38 percent to $61.2 million from $44.3 million year-on-year. Overall XENE ranks 3rd on our list of Tuesday's worst performers. While we acknowledge the potential of XENE as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than XENE but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday
We recently published an article titled . In this article, we are going to take a look at where Xenon Pharmaceuticals Inc. (NASDAQ:XENE) stands against the other stocks. Wall Street's main indices finished mixed on Tuesday, as investors digested the country's latest inflation figures, which came out lower than expected. On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, bringing the annual inflation rate to 2.3 percent, versus the 2.4 percent in March. It was the lowest annual rate since February 2021. Only the S&P 500 and the tech-heavy Nasdaq registered gains among all major indices, up by 0.72 percent and 1.61 percent, respectively. The Dow Jones, on the other hand, was down by 0.64 percent. Beyond the main indices, 10 firms lagged in performance amid negative news, sparking sell-offs. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A team of scientists in lab coats studying a biopharmaceutical molecule in a lab. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) decreased by 17.43 percent on Tuesday to finish at $29.60 apiece following the delayed results of its Phase 3 epilepsy study and a dismal earnings performance in the first quarter of the year. In a statement, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) said that the results of the study are now expected to be released in early 2026. 'While this timing represents a modest shift from our prior guidance, we are encouraged that we are nearing the end of this important study, which represents a significant milestone for Xenon, getting us one step closer to a potential first commercial product launch,' said President and CEO Ian Mortimer. In the first three months of the year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) said net loss widened by 35.7 percent to $65 million from $47.9 million in the same period last year, despite incurring $7.5 million in revenues during the period. Research and development expenses grew by 38 percent to $61.2 million from $44.3 million year-on-year. Overall XENE ranks 3rd on our list of Tuesday's worst performers. While we acknowledge the potential of XENE as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than XENE but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Washington Post
27-02-2025
- Business
- Washington Post
Xenon Pharmaceuticals: Q4 Earnings Snapshot
BURNABY, British Columbia — BURNABY, British Columbia — Xenon Pharmaceuticals Inc. (XENE) on Thursday reported a loss of $65.7 million in its fourth quarter. On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 84 cents. The results beat Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 89 cents per share.
